Beximco Pharmaceuticals PLC. — Company profile

Pharmaceutical Preparations · Bangladesh

Last price 143 BDT (At close: Oct 28, 2026) · Market cap 64.11B

Latest research: Beximco Pharmaceuticals valuation report: fair value BDT 99.2–218 (Oct 2026) · Beximco Pharmaceuticals: fair value BDT 99–218 as FY2026 EPS rises 30% to BDT 20.17

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Company profile

Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

Details

Key executives

Contact